Login

Switch On Your HIV Smarts.

Author Archives: Emily Land

Dolutegravir Shows Promise as Part of First-Line HIV Therapy

Dolutegravir Shows Promise as Part of First-Line HIV Therapy

, by Emily Land

An integrase inhibitor fared well in a head-to-head comparison with a protease inhibitor regimen for people just starting ART. Find out why this is surprising and what it could mean for treatment naïve people with high viral loads. Read More

Supervisor Wiener: Reclassifying HIV Drugs as “Specialty” is Discriminatory

Supervisor Wiener: Reclassifying HIV Drugs as “Specialty” is Discriminatory

, by Emily Land

Placing HIV and hepatitis C drugs on “specialty” tiers affects their access and affordability. Supervisor Scott Wiener called attention to this issue during a recent San Francisco hearing.
Read More

Shock & Kill: Progress in HIV Cure Research

Shock & Kill: Progress in HIV Cure Research

, by Emily Land

A new type of drug has been found to help reduce the viral reservoir by “shocking” HIV-infected cells out of latency and making them more susceptible to a killing mechanism.
Read More

Early AIDS in San Francisco: Insights from a Ward 86 Founding Physician

Early AIDS in San Francisco: Insights from a Ward 86 Founding Physician

, by Emily Land

Dr. Paul Volberding played an integral role in establishing a dedicated HIV/AIDS treatment program at San Francisco General in 1983. The San Francisco Examiner recently published a piece sharing his perspective on how far we’ve come since the early days of the epidemic. Read More

Dr. Robert Grant: What Does Ipergay Tell Us About PrEP and ‘Seasons of Risk’?

Dr. Robert Grant: What Does Ipergay Tell Us About PrEP and ‘Seasons of Risk’?

, by Emily Land

Dr. Robert Grant tells us how results from the Ipergay study inform guidance on how to stop taking PrEP if it’s no longer needed. Read More